Contribute Try STAT+ Today

Good morning, everyone, and how are you today? We are doing just fine, thank you, now that the Pharmalot campus has settled down. Our short person is hunched over a laptop for another round of learning and our official mascot is bounding up and down snow drifts. As for us, we are firing up the coffee kettle for another cup of stimulation. Our choice today is French vanilla, an old standby. Feel free to join us. Remember, no prescription is required, so no need to calculate rebates. Meanwhile, here are some choice tidbits. Hope your day goes well, and stay safe — wear a mask. …

Teva Pharmaceutical (TEVA) is in talks with other drug makers to co-produce some Covid-19 vaccines, Israel Hayom writes. Teva chief executive officer Kare Schultz said the company approached — and was approached by — vaccine makers, but he declined to name the companies with which it was in discussions. “In principle, we are positive towards contributing by manufacturing some of those vaccines that either have been approved or are just about to be approved,” he said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.